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Introduction: To reduce incidence and severity of postsurgical pain and minimize the effect of its clinical and
economic correlates, multimodal therapy for surgical patients is recommended. In this report, we discuss the use of
liposome bupivacaine, a novel multivesicular formulation of bupivacaine indicated for single-dose infiltration into
the surgical site to produce postsurgical analgesia, as part of a multimodal analgesic regimen in a patient with a
history of chronic pain scheduled to undergo laparoscopic sleeve gastrectomy. To the best of our knowledge, this
is the first published report of liposome bupivacaine in the setting of laparoscopic sleeve gastrectomy.
Case presentation: A 35-year-old white woman with morbid obesity was admitted for laparoscopic sleeve
gastrectomy to lose weight prior to hip replacement surgery. Because of a complicated medical history that included
rheumatoid arthritis, fibromyalgia, diabetes mellitus, hypertension, and chronic pain, for which she was receiving high
doses of opioid analgesics, postsurgical pain management was a concern and she was considered a candidate for
multimodal analgesia. At initiation of surgery, 50mL of lidocaine and epinephrine was infiltrated around the port sites.
At the conclusion, 25mL of normal sterile saline was added to a 20mL vial of liposome bupivacaine (266mg) and
injected around the port sites and at the site of liver retraction. Laparoscopic sleeve gastrectomy was successfully
completed. Our patient was discharged to the postanesthesia care unit for approximately four hours before discharge
to the surgical floor with a pain score of 5 (11-point scale; 0 = no pain, 10 = worst possible pain). Her postoperative
course was uneventful; no adverse events were recorded during surgery or during the remainder of her hospital stay.
Our patient was discharged on the same opioid regimen used previously for control of her preexisting chronic pain.
Conclusions: Liposome bupivacaine use in this morbidly obese patient undergoing laparoscopic sleeve gastrectomy
provided analgesic efficacy and limited postsurgical opioids to a level comparable with her baseline opioid regimen for
chronic pain. Given her complex medical history and previous issues with acute and chronic pain, we consider these
results highly successful and continue to use liposome bupivacaine as part of a multimodal analgesic regimen in an
effort to optimize postsurgical pain management.
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Postsurgical pain is a potentially significant complication
across a wide range of surgical procedures and has been
found to contribute to increased risk of hospital readmis-
sion, increased per-patient costs [1], and decreased health-
related quality of life in the immediate postsurgical period
[2]. In an effort to reduce the incidence and severity ofCorrespondence: pbertin@ExcelaHealth.org
Excela Health Westmoreland Hospital, 532 West Pittsburgh Street,
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reproduction in any medium, provided the orpostsurgical pain, as well as the impact of its clinical and
economic correlates, a task force established by the
American Society of Anesthesiologists (ASA) has strongly
endorsed multimodal therapy for surgical patients [3].
Multimodal analgesia involves the use of two or more
drugs with differing mechanisms of action in an effort to
maximize analgesic efficacy while reducing the risk and
severity of adverse events (AEs) [3].
In this report, we discuss the use of liposome bupivacaine
(EXPAREL®; Pacira Pharmaceuticals, Inc., Parsippany, NJ,
USA), a novel multivesicular formulation of bupivacaineis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to produce postsurgical analgesia [4]. It was used as part
of a multimodal analgesic regimen in a patient who had a
history of chronic pain and was scheduled to undergo lap-
aroscopic sleeve gastrectomy (LSG).
Case presentation
A 35-year-old white woman with morbid obesity (height,
5 feet 1.5 inches; weight, 305 pounds; body mass index,
56kg/m2) and normal renal function (baseline creatinine,
0.6mg/dL) was admitted to our institution for LSG. She
required weight loss in order to qualify for hip replace-
ment surgery. Her past medical history was significant
for rheumatoid arthritis, fibromyalgia, diabetes mellitus,
hypertension, and obstructive sleep apnea. Our patient
also had a history of chronic pain, for which she was
receiving high doses of opioid analgesics (including
transmucosal fentanyl, controlled-release oral morphine,
and oral tramadol; see Table 1). The source of our patient’s
pain was mostly in her joints, as a result of rheumatoidTable 1 Opioid use at baseline and after laparoscopic sleeve







600μg × 4 15mg
Morphine CR, oral 30mg × 2 10mg
Tramadol, oral 50mg as needed NAa
Administered in the operating room
1 Fentanyl, IV 925μg × 1 92.5m
Administered in the postanesthesia care unit
1 Hydromorphone, IV 0.5mg × 6 3.3mg
Administered during hospital stay
1 Transmucosal fentanyl
citrate, oral
200μg × 2 5mg
Morphine CR, oral 30mg × 1 10mg
Hydromorphone, IV 1mg × 4 6.7mg
Oxycodone + APAP,
oral solution
10mg × 1 5mg
2 Transmucosal fentanyl
citrate, oral
600μg × 2 15mg
Morphine CR, oral 30mg × 2 10mg
Hydromorphone, IV 1mg × 3 6.7mg
Oxycodone + APAP,
oral solution
10mg × 3 5mg
5mg × 2 2.5mg
3 (before discharge) Transmucosal fentanyl
citrate, oral
600μg × 3 15mg
Morphine CR, oral 30mg × 1 10mg
Oxycodone + APAP,
oral solution
10mg × 1 5mg
aConversion of oral tramadol to morphine equivalent not available. APAP, acetaminarthritis. In addition, our patient reported previously
experiencing severe pain necessitating a prolonged hospital
stay (>2 days) following a standard laparoscopic cholecyst-
ectomy. Given our patient’s history of both acute postsurgi-
cal and chronic pain and high baseline opioid usage, she
was a desirable candidate for an opioid-reducing, multi-
modal pain management strategy.
At the initiation of surgery prior to trocar insertion,
50mL of 1% lidocaine and epinephrine (1:100,000) was
infiltrated around the port sites. At the conclusion of the
procedure (which was more than 20 minutes after admin-
istration of the lidocaine), 25mL of 0.9% preservative-free
normal sterile saline was added to a 20-mL vial of lipo-
some bupivacaine (266mg) for a total volume of 45mL. It
was injected using a spinal needle around the port sites
(Figure 1): the flanking 5-mm port sites received 5mL
each; the central 12-mm ports, 15mL each; and 5mL was
infused at the site of liver retraction. The dose of liposome
bupivacaine was based on the surgical site and the volume




equivalent dose per drug
Total daily IV morphine
equivalent opioid dose
60mg
















ophen; CR, controlled-release; IV, intravenous; NA, not applicable.
Figure 1 Laparoscopic view of infiltration of liposome bupivacaine at 12-mm port site. (a) Insertion of needle into deep tissue layers.
Advancement of needle is stopped just prior to penetration of the parietal peritoneum. (b) Infiltration of liposome bupivacaine and dispersion of
fluid to form a wheal (outlined by white oval). This process was repeated in four quadrants around the site of the trocar to form a field block.
Photographs courtesy of Peter M. Bertin, DO.
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directly into the deep tissue with the needle. The needle
was slowly withdrawn so that infiltration of liposome
bupivacaine was targeted primarily to the myofascial level.
Our patient was administered a total of 925μg of IV fen-
tanyl during surgery.
LSG was successfully completed. Our patient was dis-
charged to the postanesthesia care unit, where she
stayed for approximately four hours before discharge to
the surgical floor with a pain score of 5 (11-point scale;
0 = no pain, 10 = worst possible pain). The postoperative
course was uneventful; no AEs were recorded during
surgery or during the remainder of our patient’s hospital
stay. Her pain scores ranged from 5 to 8 during her hos-
pital stay; however, this was consistent with her pain
before surgery, which was always ≥4 due to her history of
chronic pain. She reported that the majority of her pain
was musculoskeletal in location and related to her rheuma-
toid arthritis and fibromyalgia and not related to the surgi-
cal site. Analgesic medications administered to the patient
are summarized in Table 1 and included intravenous(IV) hydromorphone, oral transmucosal fentanyl citrate,
controlled-release morphine tablets, and oxycodone/acet-
aminophen oral solution. In order to facilitate comparisons,
opioid doses have been converted to their IV morphine
equivalents. Total opioid use (IV morphine equivalent) was
51.8mg on day 1 (after surgery), 90.1mg on day 2, and
60mg on day 3 (before discharge).
Our patient was discharged routinely two days after
surgery, with the same home medication regimen as before
surgery, along with a prescription for oxycodone/acet-
aminophen 5/325mg four times daily as needed.
Discussion
Given our patient’s complicated medical history and
experience with both acute postsurgical and chronic
pain, there was a strong expectation of significant acute
postsurgical pain after LSG, which would have normally
required increased opioid use for adequate pain control.
Opioid use is problematic in obese patients: calculation
of adequate doses is difficult using traditional body sur-
face area measurements, given the disparity between lean
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susceptible to opioid-induced respiratory depression;
and opioid use may exacerbate obstructive sleep apnea
in affected patients [5,6]. These are the issues that
dissuaded us from the routine postsurgical use of patient-
controlled analgesia, which, combined with inadequate
supervision during hospitalization, can result in exces-
sive opioid use and increased risk of AEs in obese
patients.
These considerations supported the use of multimodal
analgesia consistent with ASA recommendations; how-
ever, we remained concerned about the potential for
adequate pain control given the duration of action of most
local anesthetics (<10 hours) [7,8]. Therefore, we adminis-
tered liposome bupivacaine, a multivesicular formulation
of bupivacaine designed to allow diffusion of the drug over
an extended period, around the surgical ports and at the
site of liver retraction. In a pivotal soft tissue trial (hemor-
rhoidectomy), liposome bupivacaine was shown to provide
postsurgical analgesia and reduce opioid use for 72 hours
after surgery [4,9]. To the best of our knowledge, this is
the first published report of a multimodal analgesic regi-
men involving liposome bupivacaine in the setting of
LSG. It should be noted that in our practice, we now
infiltrate liposome bupivacaine preemptively at the start
of the procedure and no longer administer lidocaine plus
epinephrine. Additionally, we now add 40mL of 0.9%
preservative-free normal sterile saline to a 20-mL vial of
liposome bupivacaine (266mg) for a total volume of
60mL for LSG procedures, in contrast to the total vol-
ume of 45mL used in the current report. In our experi-
ence, the increased volume results in greater dispersion
of liposome bupivacaine and, thus, potentially improved
nerve coverage.
Common AEs following administration of liposome
bupivacaine include nausea, constipation, and vomiting.
Common neurologic AEs include dizziness, headache,
somnolence, hypoesthesia, and lethargy; common car-
diac AEs include tachycardia and bradycardia [4]. Our
patient’s postsurgical stay was not complicated by any
liposome bupivacaine-related AEs, opioid-related AEs
(for example, nausea, constipation, respiratory depression),
or by inadequate pain control; the length of stay (two
days) was consistent with expectations. The patient was
discharged on the same opioid regimen used previously
for control of her preexisting chronic pain. Notably,
during her inpatient stay, her use of opioids between
surgery and discharge (51.8mg, 90.1mg, and 60mg IV
morphine equivalent on days 1, 2, and 3, respectively)
was comparable to her baseline daily opioid usage (80mg
IV morphine equivalent plus tramadol as needed), even
during the time period (≥12 hours) when the efficacy
of conventional local anesthetics would be expected
to wane.Conclusions
The use of liposome bupivacaine in this patient with mor-
bid obesity undergoing LSG provided analgesic efficacy
and limited the postsurgical use of opioids to a level com-
parable with the patient’s baseline opioid regimen for
chronic pain. In light of the patient’s complex medical his-
tory and previous issues with acute and chronic pain, we
consider these results highly successful and continue to
use liposome bupivacaine as part of a multimodal anal-
gesic regimen in an effort to optimize postsurgical pain
management.
Patient’s perspective
Following the gastrectomy, I lost sufficient weight and
was able to have a hip replacement surgery. After my
hip replacement surgery, the doctors changed some of
my chronic pain medications around and I had many is-
sues with pain control. I was in the hospital for 20 days.
Of the six major surgeries I have had in my life, the re-
covery from this gastrectomy was the most pain-free
and fastest of all.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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